An Analytical Approach to Enhance Recruitment of Rheumatoid Arthritis Patients

No single blood test or physical finding alone can confirm the diagnosis of rheumatoid arthritis (RA). However, two tests that detect markers of inflammation are often ordered when RA is suspected: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Other common tests include rheumatoid factor and anti-CCP antibodies.

RA Map

RA patients in the United States

While the test results are clearly valuable to the requesting physician to inform diagnostic decisions, sponsors can also leverage this information to support patient recruitment in an increasingly competitive space. We recently evaluated how de-identified patient data from these common tests run by LabCorp can support sponsors’ clinical trials in rheumatoid arthritis. Continue reading

Going with the Flow: Key Flow Cytometry Challenges and Solutions at CYTO 2017

When it comes to novel drug discovery and development, flow cytometry is known for Flow Cytometer blogbeing both a powerful and versatile technology. It can deliver valuable information to advance early biomarker development, tolerability, clinical studies and even companion diagnostics. But leveraging flow cytometry technologies to answer analytical questions and empower decision making from the research lab to the clinic requires a deep knowledge of cutting-edge approaches.

Virginia Litwin, PhD, principal scientist, hematology/flow cytometry at Covance and her team are examining current trends in rare event analyses assays to ensure that performance is well characterized and fit-for-purpose – particularly in regulated environments. They are also addressing the various hurdles associated with analyzing cellular biomarkers for immunotherapy and adoptive cell therapy. Continue reading

Covance and Arcinova Providing Integrated Services

Providing integrated services to the global biotech and pharma industry

Covance and Arcinova recently expanded a strategic relationship following the signing of a sales services agreement at the end of 2016. Under the terms of the agreement, Covance is offering Arcinova services alongside its own extensive range of drug development capabilities.

Arcinova is a contract research and development organization based in Alnwick, UK. The Company provides small molecule drug substance, product and analytical support from preclinical through to Phase II. Since its inception in February 2016, Arcinova has built on the legacy customer base developed when it was a Covance site, and is now serving biotechnology and pharmaceutical companies on four continents. Continue reading

An Agile, Career-Focused Business Develops From Within

Jonathan Zung, Group President, Clinical Development & Commercialization Services, has only been at Covance for a short time, but he already has big plans Jonathan Zung Careers Blog An Agile, Career-Focused Business Develops From Within Covancefor the future of our clinical and commercialization businesses, as well as fresh ideas on talent development.

We recently spoke with him to learn more about his passion for operational excellence, and ideas for helping us develop and nurture our own careers. Continue reading

A Holistic View of the Biosimilars Landscape: Key Factors for Clinical and Commercial Success

Biosimilars have dominated the headlines in the U.S. with several FDA approvals, legal battles and questions around reimbursement, placing an increased focus on  Biosimilars Landscape: Key Factors for Clinical and Commercial Successhow to successfully navigate this relatively new pathway from end to end.

Starting with the regulatory environment to CMC bioanalytics and pharmacodynamics, learn how drug developers can understand regulatory differences and identify a fit-for-purpose program. We will also cover how to proactively identify key issues for both PK equivalence and Phase III equivalence studies, and initiate market access and commercialization approaches. Continue reading

Hot Topics Discussed in Covance Spring & Summer Webinars

Unlock opportunities for your clinical research programs and deliver results that Covance Spring Webinars Video Nash Diabetic Heart Biomarkersmatter.
We’re excited to be on the cutting edge of drug development solutions. Take a look at our recent webinar topics and leverage our experience.

Assessing Abuse Potential of CNS-Active Compounds:  Regulatory Environment & Challenges

Learn about the regulatory environment for the assessment of abuse potential of CNS-active drugs, explore the importance of early vetting of abuse potential and identify critical steps in your regulatory strategy.

June 29, 11 a.m. EDT | Register Now

Continue reading

Clinical & Research Excellence Awards Shortlist Xcellerate Medical Review

Covance is excited to announce that Xcellerate® Medical Review has been named a finalist in the Clinical & Research Excellence (CARE) Awards. As a finalist in the Best Sponsor-Focused Technological Development category, Xcellerate Medical Review is Clinical & Research Excellence Awards Shortlist Xcellerate Medical Reviewbeing recognized for its modern approach to improving the clinical trial process. The CARE Awards recognize excellence across the global clinical research enterprise.

The Xcellerate Medical Review informatics product provides a critical function to study sponsors to safeguard subject safety, increase the robustness and quality of clinical trial execution, improve the reliability of investigational data and ensure adherence to ethical standards. Xcellerate Medical Review is a part of the larger award-winning Xcellerate Clinical Trial Optimization® suite, a comprehensive informatics solution that can meaningfully reduce the cost, time, complexity and risk of drug development. Continue reading

The Biosimilars Landscape: What All Developers Need to Know

As biosimilars to treat rheumatic diseases begin get approval from the FDA, biosimilar development remains a hot topic in drug development. Sponsors estimate Covance Contract Research Org Biosimilars Webinar 2a 35% growth of biosimilars in their development pipelines by 2020, but face a wide variety of regional and global markets along with shifting guidelines and recommendations, stressing the need to understand this rapidly changing landscape. What is the real potential for clinical and health-economic benefits offered by these agents?  Continue reading

Keeping Skills Sharp For CRAs

The drug industry is evolving and clinical trials are becoming more complex. How do CRAs in a large global company keep their skills up to date? Recognizing that large group meetings are costly and virtual training feels impersonal, Covance decided to address this challenge with an innovative model called CLIK: Country Leadership Imparting Knowledge.Covance CRA Careers

With selected leaders identified from each of the 70+ countries that Covance serves, the CLIK program brings CRAs face-to-face to share their experiences, gain new knowledge and then serve as training representatives for peers in their own regional teams. Continue reading

Understanding Regulatory and Market Access Considerations With Drug Abuse Potential

Each assessment for abuse liability is as unique as the molecule in question, reiterating Regulatory And Market Access Considerations With Drug Abuse Potentialthe importance of early awareness, understanding the current regulatory landscape, and being able to plan your development and post-marketing accordingly.

In our previous blog post, we focused on the value of early drug abuse potential testing. In this blog, we’ll delve into important regulatory and market access considerations for abuse liability testing that can help drug developers maximize the potential of their molecule.

Continue reading